Palvella Therapeutics (PVLA) director receives 3,000 stock options grant

Rhea-AI Filing Summary

PALVELLA THERAPEUTICS, INC. director John Doux received a grant of stock options covering 3,000 shares of common stock. The options have an exercise price of 102.1900 per share and expire on 2036-06-10.

These options vest upon the earlier of the first anniversary of the 2026-06-10 grant date or the company’s next annual stockholder meeting, subject to his continued service. Following this compensation-related grant, Doux holds 3,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Doux John

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	3,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 3,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 3,000 options Exercise price: 102.1900 per share Expiration date: 2036-06-10 +2 more

5 metrics

Options granted 3,000 options Stock Option (Right to Buy) granted 2026-06-10

Exercise price 102.1900 per share Conversion or exercise price of granted options

Expiration date 2036-06-10 Options expiration

Underlying shares 3,000 shares Common stock underlying the granted options

Holdings after grant 3,000 options Total derivative holdings following transaction

Key Terms

Stock Option (Right to Buy), grant/award acquisition, exercise price, vesting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

grant/award acquisition financial

"transaction_action: "grant/award acquisition""

exercise price financial

"conversion_or_exercise_price: "102.1900""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares subject to this option shall vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the Issuer's next annual meeting of stockholders"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: "2036-06-10T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/12/2026 - 04:07 PM Accepted by SEC EDGAR 06/12/2026 - 04:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doux John

(Last) (First) (Middle)

C/O PALVELLA THERAPEUTICS, INC.

353 W. LANCASTER AVENUE, SUITE 200

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PALVELLA THERAPEUTICS, INC. [ PVLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$102.19	06/10/2026		A		3,000		(1)	06/10/2036	Common Stock	3,000	$0	3,000	D

Explanation of Responses:

1. The shares subject to this option shall vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the Issuer's next annual meeting of stockholders following the grant date, subject in each case to the Reporting Person's continued service through the applicable vesting date.

	/s/ Kathleen A. McGowan, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Palvella Therapeutics (PVLA) report for John Doux?

Palvella Therapeutics reported that director John Doux received a grant of stock options for 3,000 shares of common stock. The award is a compensation-related grant, not an open-market purchase or sale, and increases his derivative holdings in the company.

What are the key terms of John Doux’s new stock options at Palvella Therapeutics (PVLA)?

John Doux’s stock options cover 3,000 shares of Palvella Therapeutics common stock at a 102.1900 exercise price, expiring on 2036-06-10. These options give him the right to buy shares at that price once they vest and remain outstanding until expiration.

When do John Doux’s Palvella Therapeutics (PVLA) stock options vest?

The options vest on the earlier of the first anniversary of the 2026-06-10 grant date or the next annual meeting of stockholders following that date. Vesting in both cases requires John Doux to continue serving the company through the applicable vesting date.

Is John Doux’s Palvella Therapeutics (PVLA) Form 4 transaction a market buy or sell?

The Form 4 shows a grant of stock options to John Doux, classified as a grant or award acquisition. It is not an open-market buy or sell, but a compensation-related derivative award that increases his potential future equity exposure to the company.

How many Palvella Therapeutics (PVLA) options does John Doux hold after this grant?

After this grant, John Doux directly holds 3,000 stock options linked to Palvella Therapeutics common stock. These options are exercisable for 3,000 underlying shares once vested and remain outstanding until their stated expiration date in 2036, barring other changes.